Preliminary study on reducing oral moist snuff use

Drug and Alcohol Dependence

Volumn 70, Issue 2, 2003, Pages 215-220

  Hatsukami, Dorothy K ^a   Edmonds, Amanda ^a   Schulte, Susan ^a   Jensen, Joni ^a   Le, Chap T ^a   Losey, London ^a   Carmella, Steven G ^a   Hecht, Stephen S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Carcinogens; Snuff tobacco; Tobacco exposure reduction

Indexed keywords

CARCINOGEN; COTININE; NICOTINE GUM; NITROSAMINE;

ADULT; ARTICLE; CONTROLLED STUDY; EXPOSURE; FEASIBILITY STUDY; FOLLOW UP; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; REDUCTION; SMOKELESS TOBACCO; SMOKING CESSATION; TECHNIQUE;

MENTHA; NICOTIANA TABACUM;

EID: 0042921410     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00006-1     Document Type: Article

References (15)

1. Bolinder G. Long-term use of smokeless tobacco. Cardiovascular mortality and risk factor. Stockholm: Repro. Print AB; 1997.
2. Burns D. Estimating the benefits of a risk reduction strategy. Poster presented at the Society for Research on Nicotine and Tobacco 3rd Annual Scientific Conference, Nashville; 1997.
3. Djordjevic M., Hoffman D., Glynn T., Connolly G. US commercial brands of moist snuff, 1994. I. Assessment of nicotine, moisture, and pH. Tob. Control. 4:1995;62-66.
4. Hatsukami D., Grillo M., Boyle R., Allen S., Jensen J., Bliss R., Brown S. Treatment of spit tobacco users with transdermal nicotine system and mint snuff. J. Consult. Clin. Psychol. 68:2000;241-249.
5. Hatsukami D., Jensen J., Allen S., Grillo M., Bliss R. The effects of behavioral and/or pharmacological treatment on smokeless tobacco users. J. Consult. Clin. Psychol. 64:1996;153-161.
6. 3 receptors in mediating subjective and behavioral responses to cotinine, Pharmacol., Biochem. Behav. In press.
7. Hatsukami D., Severson H. Oral spit tobacco: addiction, prevention and treatment. Nicotine Tob. Res. 1:1999;21-44.
8. Hecht S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 91:1999;1194-1210.
9. Hecht S.S. Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 11:1998;559-603.
10. Hecht S., Rivenson A., Braley J., DiBellow J., Adams J., Hoffmann D. Induction of oral cavity tumors in F344 rats by tobacco-specific nitrosamines and snuff. Cancer Res. 46:1986;4162-4166.
11. Hoffmann D., Djordjevic M.V., Fan J., Zang E., Lynn T., Connolly G.N. Five leading US commercial brands of moist snuff in 1994: assessment of carcinogenic N-nitrosamines. J. Natl. Cancer Inst. 87:1995;1862-1869.
12. Henningfield J., Radzius A., Cone E. Estimation of available nicotine content of six smokeless tobacco products. Tob. Control. 4:1995;57-61.
13. Littell R., Milliken G., Stroup W., Wolfinger R. SAS system for mixed models. 1996;SAS Institute, Inc, Cary, NC.
14. Stratton K., Padma S., Wallace R., Bondurant S. Institute of Medicine. Clearing the smoke: assessing the science base for tobacco harm reduction. 2001;National Academy Press, Washington DC.
15. Tomar S., Winn D., Swango G., Giovino G., Kleinman D. Oral mucosa smokeless tobacco lesions among adolescents in the United States. J. Dent. Res. 76:1997;1277-1286.